Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Jeon, Young-Woo  [Clear All Filters]
2024
Park S, Bang S-Y, Kwag D, Lee JHyuk, Kim TYoon, Lee J, Min GJune, Park SSoo, Yahng S-A, Jeon Y-W, et al. Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1. Bone Marrow Transplant. 2024.
2023
Park S-S, Shin S-H, Lee J-Y, Jeon Y-W, Yhang S-A, Min C-K. Prospective Comparative Study of Etoposide plus G-CSF versus G-CSF Alone, Followed by Risk-Adapted Plerixafor for Peripheral Blood Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma: CAtholic REsearch Network for Multiple Myeloma Stu. Cancers (Basel). 2023;15(19).
Min G-J, Jeon Y-W, Kim TYoon, Kwag D, Kim B-S, Lee J, Lee JHyuk, Park S-S, Park S, Yoon J-H, et al. The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma. Sci Rep. 2023;13(1):17496.
2022
Kim Y, Park S-S, Jeon Y-W, Yahng S-A, Shin S-H, Min C-K. Response and dynamics of renal function for transplant-eligible multiple myeloma patients who were treated with novel agent: The CAREMM-2201 study. Transplant Cell Ther. 2022.
2021
Cho B-S, Yahng S-A, Min G-J, Park S, Park S-S, Shin S-H, Jeon Y-W, Yoon J-H, Lee S-E, Eom K-S, et al. Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual disease for acute myeloid leukemia in elderly patients. Transplant Cell Ther. 2021.
2020
Park S, Min GJune, Park SSoo, Yahng S-A, Jeon Y-W, Shin S-H, Yoon J-H, Lee S-E, Cho BSik, Eom K-S, et al. Comparison of myeloablative (CyTBI, BuCy) versus reduced-intensity (FluBu2TBI400) peripheral blood stem cell transplantation in acute myeloid leukemia patients with pre-transplant low WT1 expression. Biol Blood Marrow Transplant. 2020.
Shin S-H, Park S-S, Park S, Jeon Y-W, Yoon J-H, Yahng S-A, Cho B-S, Kim Y-J, Lee S, Kim H-J, et al. Nonmyeloablative matched sibling stem cell transplantation with the optional reinforced stem cell infusion for patients with hemoglobinopathies. Eur J Haematol. 2020.
2019
Lee S-E, Lim J-Y, Bin Ryu D-, Kim TWoo, Park SSoo, Jeon Y-W, Yoon J-H, Cho B-S, Eom K-S, Kim Y-J, et al. Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2019.
Cho B-S, Jeon Y-W, Hahn A-R, Lee T-H, Park S-S, Yoon J-H, Lee S-E, Eom K-S, Kim Y-J, Lee S, et al. Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia. Cancer Med. 2019.
Jeon Y-W, O J-H, Park K-S, Min GJune, Park S-S, Yoon J-H, Eom K-S, Min C-K, Cho S-G. Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP. Br J Haematol. 2019.
Cho B-S, Min G-J, Park S-S, Shin S-H, Yahng S-A, Jeon Y-W, Yoon J-H, Lee S-E, Eom K-S, Kim Y-J, et al. WT1 measurable residual disease assay in AML who underwent allogeneic hematopoietic stem cell transplantation; optimal time points, threshold, and candidates. Biol Blood Marrow Transplant. 2019.
2018
Park S-S, Jeon Y-W, Min GJune, Park S, Yahng S-A, Yoon J-H, Shin S-H, Lee S-E, Cho B-S, Eom K-S, et al. Graft-versus-host disease free, relapse-free survival after allogeneic stem cell transplantation for myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018.
2015
Kim N, Nam Y-S, Im K-I, Lim J-Y, Lee E-S, Jeon Y-W, Cho S-G. IL-21-expressing mesenchymal stem cells prevent lethal B-cell lymphoma through efficient delivery of IL-21, which redirects the immune system to target the tumor. Stem Cells Dev. 2015.
Yoon J-H, Kim H-J, Jeon Y-W, Lee S-E, Cho B-S, Eom K-S, Kim Y-J, Lee S, Min C-K, Cho S-G, et al. Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations. Genes Chromosomes Cancer. 2015.
Kim N, Jeon Y-W, Nam Y-S, Lim J-Y, Im K-I, Lee E-S, Cho S-G. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells. Cytokine. 2015;78:22-26.